Literature DB >> 25519267

Dissections of regional lymph nodes for treatment of skin cancer: predicting annual caseloads that will optimise outcomes.

J K Dickson1, A Davies, S Rahman, C Sethu, J R O Smith, A Orlando, D Ayers.   

Abstract

INTRODUCTION: Dissection of regional lymph nodes (RLNs) can lead to significant morbidity and a high prevalence of complications. Published guidance states that these procedures should be carried out by surgeons who are members of a specialist skin multidisciplinary team who carry out a combined minimum of 15 axillary/groin dissections per year. However, there is little evidence to guide this minimum figure of procedures. We report on the burden of service provision and prevalence of complications across the South West of England and Wales.
METHODS: A 12-month review of dissections of RLNs for skin cancer was undertaken covering five Plastic Surgery Units with a collective catchment of 8.4 million people. Detailed data were collected on patient demographics, pathology, timing of surgery, and prevalence of complications.
RESULTS: A total of 163 dissections were carried out. Forty-three per cent of patients experienced one or more complication. In that 12-month period, an average of 8 axillary/groin dissections was carried out per surgeon. A funnel plot demonstrated that the prevalence of complications for individual surgeons was within the limit of the plot but, in many cases, this was based only on a relatively small number of procedures per consultant. If surgeons carried out 10 procedures per year, the upper and lower limits on the plot were 73% and 11%, respectively.
CONCLUSIONS: Funnel plots can provide a useful guide as to whether the prevalence of complications for procedures for individual surgeons lies within acceptable limits. Based on these results, 10 procedures per consultant per year should be sufficient to enable meaningful assessment of the prevalence of complications.

Entities:  

Mesh:

Year:  2015        PMID: 25519267      PMCID: PMC4473900          DOI: 10.1308/003588414X14055925059390

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  15 in total

1.  Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

Authors:  F Egberts; C Hartje; C Schafmayer; K C Kaehler; W von Schönfels; A Hauschild; T Becker; J H Egberts
Journal:  Ann R Coll Surg Engl       Date:  2011-10       Impact factor: 1.891

2.  Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients.

Authors:  Sharon B Chang; Robert L Askew; Yan Xing; Storm Weaver; Jeffrey E Gershenwald; Jeffrey E Lee; Richard Royal; Anthony Lucci; Merrick I Ross; Janice N Cormier
Journal:  Ann Surg Oncol       Date:  2010-03-25       Impact factor: 5.344

3.  Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection.

Authors:  Lutz Kretschmer; Kai-Martin Thoms; Sabine Peeters; Holger Haenssle; Hans-Peter Bertsch; Steffen Emmert
Journal:  Melanoma Res       Date:  2008-02       Impact factor: 3.599

4.  Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma.

Authors:  Merlin M Guggenheim; Urs Hug; Florian J Jung; Valentin Rousson; Matthias C Aust; Maurizio Calcagni; Walter Künzi; Pietro Giovanoli
Journal:  Ann Surg       Date:  2008-04       Impact factor: 12.969

5.  Axillary lymph node dissection for malignant melanoma.

Authors:  Paul G Davis; Jonathan W Serpell; John W Kelly; Eldho Paul
Journal:  ANZ J Surg       Date:  2011-06       Impact factor: 1.872

6.  Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity.

Authors:  Jamshaid Ul-Mulk; Lisbet Rosenkrantz Hölmich
Journal:  Dan Med J       Date:  2012-06       Impact factor: 1.240

7.  Early mobilization after ilio-inguinal lymph node dissection for melanoma does not increase the wound complication rate.

Authors:  K P Wevers; H P A M Poos; R J van Ginkel; B van Etten; H J Hoekstra
Journal:  Eur J Surg Oncol       Date:  2012-09-13       Impact factor: 4.424

Review 8.  Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma.

Authors:  Amod A Sarnaik; Christopher A Puleo; Jonathan S Zager; Vernon K Sondak
Journal:  Cancer Control       Date:  2009-07       Impact factor: 3.302

9.  Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

Authors:  Bryan H Burmeister; Michael A Henderson; Jill Ainslie; Richard Fisher; Juliana Di Iulio; B Mark Smithers; Angela Hong; Kerwin Shannon; Richard A Scolyer; Scott Carruthers; Brendon J Coventry; Scott Babington; Joao Duprat; Harald J Hoekstra; John F Thompson
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316

10.  Revised U.K. guidelines for the management of cutaneous melanoma 2010.

Authors:  J R Marsden; J A Newton-Bishop; L Burrows; M Cook; P G Corrie; N H Cox; M E Gore; P Lorigan; R MacKie; P Nathan; H Peach; B Powell; C Walker
Journal:  Br J Dermatol       Date:  2010-07-01       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.